A Chimeric Signal Peptide-Galectin-3 Conjugate Induces Glycosylation-Dependent Cancer Cell-Specific Apoptosis.

CONCLUSIONS: We demonstrate that sGal-3 kills aberrantly glycosylated tumor cells and antagonizes tumor growth through a novel integrin b1-dependent cell-extrinsic apoptotic pathway. These findings provide proof of concept that aberrant N-oncoglycans represent valid cancer targets and support further translation of the chimeric sGal-3 peptide conjugate for cancer therapy.
PMID: 31969339 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 21, 2020 Category: Cancer & Oncology Authors: Van Meir EG, Lee SH, Rehman FK, Tyler KC, Yu B, Zhang Z, Zerrouqi A, Kaluzova M, Hadjipanayis CG, Cummings RD, Olson JJ, Devi NS, Osuka S Tags: Clin Cancer Res Source Type: research